Celgene Corporation (NASDAQ:CELG) has a 1 Year Target Estimate of $137.91. The stock traded with the volume of 5.47 Million in the last trading session. Celgene Corporation opened at $122.96 and closed by showing a decrease of -2.96%. The Bid price in the last session was $119.60 x 200 and the Ask price was $120.21 x 500. (The ask price is what sellers are willing to take for it. If you are selling a stock, you are going to get the bid price, if you are buying a stock you are going to get the ask price. The difference (or spread) goes to the broker/specialist that handles the transaction).
Celgene Corporation has the Market Capitalization of 91.87 Billion. The Stock has its 52-week High of $127 and 52-Week Low of $93.05 and it touched its 52-week high on Nov 9, 2016 and 52-Week Low on Feb 3, 2016.
Celgene Corporation reported its last Earnings on Oct 27 BMO where the company reported Actual EPS of $1.58/Share whereas, the Analyst Estimated EPS was $1.48/share. The difference between Actual EPS and Estimated EPS was $0.1/share. This represented an Earnings Surprise of 6.8%. The company will report its next earnings on Jan 26 – Jan 30 (Est.).
Some analyst provided their insight on Growth Estimates; Celgene Corporation has the Current Quarter Earnings Growth rate of 34.7%. The Next Quarter growth is expected to be 22.7%. In the past 5 years, the stock has earnings growth rate of 24.64% per annum while the Upcoming 5 year’s earnings growth rate is expected to be 22.53% per annum.
23 number of analysts also provided their insight on Celgene Corporation, where the Average Price Target for the stock is $137.91. They also projected Low Price Target as $92 while High Price Target is set at $162.
A number of analysts rated the stock as well: 11 analysts believe that the stock is a STRONG BUY while 12 reported it as Buy.4 analysts assigned a HOLD rating, 1 said it’s UNDERPERFORM and 0 say that this stock is a SELL.
Celgene Corporation annual Divided is 0 while it’s Dividend Yield is 0%. The stock has its Price to Earnings (P/E) ratio of 44.91 and Forward Price to Earnings ratio of 16.81. The company has its Price to Sales (P/S) ratio of 8.5 where Price to Book (P/B) ratio of 16.28, Price to Cash Per share (P/C) of 13.38 and Price to Free Cash Flow (P/FCF) has a value of 27.17.
The company has its Return on Assets (ROA) of 8 Percent. Return on Equity (ROE) stands at 38.4% and Return on Investment (ROI) displays a value of 8.9%.
The stock is currently trading at Distance from 20-Day simple moving Average of 1.99% whereas, Distance from 50-Day Simple moving average is 9.33 Percent and Distance from 200-Day Simple Moving Average of 12.08 percent.
A look at performance overview of Celgene Corporation depicts that Performance (Week) is -2.03 percent while Performance Month is 15.98%. Quarterly performance shows a value of 11.03% and Half Year Performance value stands at 9.49%. Yearly performance of the stock has the value of 7.19 percent. Celgene Corporation has its YTD performance of -1.04 Percent. (YTD performance is the most important factor to consider; if YTD is negative, the stock is declining; if the YTD Performance value is Positive the stock is surging).
Many Insiders have done trades inside the company. The latest trade was made on 9 Nov 2016 where Officer Pehl (Michael F) did a transaction type “Buy” in which 1876 shares were traded at a price of $59.24. Another insider trade includes Officer Pehl (Michael F) who also initiated a transaction in which 1668 shares were traded on 9 Nov 2016 as “Buy”. On 9 Nov 2016 Officer Pehl (Michael F) traded 1628 shares as “Sell” at $121.15. Officer Pehl (Michael F) Buy 625 shares on 9 Nov 2016 at the price of $118.57.
The latest Upgrades/Downgrades was done by Research firm Standpoint Research on 9-Nov-16 who Downgrade the stock from Buy to Hold. Other firms have also Upgraded/Downgraded the stock. On 8-Nov-16, Mizuho took an action “Initiated” to Buy. On 15-Jul-16, the stock was Initiated to Buy by Stifel.